Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by edroseon Oct 20, 2019 9:55am
110 Views
Post# 30248516

Listen to last agm what they answered the question

Listen to last agm what they answered the questionWhen they where asked why they kept 10 million debt on the books and they put pli’s ip and assets as collateral Galbraith stated we didn’t want to dilute shares. Do you believe that was the real reason the kept that 10 million debt  listen to what best said     

When  several people will be questioned under oath the truth will come out 
imagine when  people like kory sorenson,Louise menard,pl,Simon best,ex and current board members,pli’s scientist who can clearly tells us why few checkpoints are taking so long,fda correspondence, big pharma’s Negotiators who dealt with pli telling us why not one company was interested in partnering with pli why they where not interested in buying some assets ,did the fact thomvest had pli’s Ip and assets as collateral maybe a problem,when they stated we had no choice in shutting down the atm they just approved few months before up to 50 million ;why approve an atm and shut it down. It will be easy to see if it’s true they had no choice ;
same thing with ivig we had to put it on hold (why put on hold a phase 3 drug) and they take a q50 accounting write down that they will benefit from read the details   Is it true they had no choice 

is it true they had exhausted all options to raise capital to continue and they had ONLY ONE OPTION AND THAT WAS TO DECLARE HARDSHIP AND WIPE OUT RETAIL INVESTORS AND TAKEOVER PLI 
‘the truth will come out
<< Previous
Bullboard Posts
Next >>